New hip implant slashes dislocation risk by 70 percent in Swedish-British study

A groundbreaking Swedish-British study has introduced a new type of hip implant that significantly reduces the risk of dislocation, a common and painful complication following hip replacement surgery. The research, involving over 1,500 patients, found that this innovative implant lowers the chance of the artificial hip ball popping out of its socket by a remarkable 70 percent.

Each year, approximately 18,000 older individuals in Sweden, predominantly women, suffer hip fractures, often due to falls. For about 2,000 of these patients, a complete hip joint replacement with a prosthetic is performed. However, a significant issue arises for roughly eight percent of these patients, as the new hip ball dislocates, causing considerable pain. The study compared 779 patients who received the new implant against 787 who received a standard model. After one year, 4.2 percent of patients with standard prosthetics experienced dislocation, compared to just 1.3 percent with the new implant.

“

It's like two joints in one joint.

The innovative design features a dual-ball system: a small metal ball moves freely within a larger plastic ball, which in turn moves within a metal socket. This contrasts with standard prosthetics, which consist of a single metal ball within a plastic socket. "It's like two joints in one joint," explained Nils Hailer, a senior physician at Uppsala University Hospital and a lead researcher on the study.

“

For Sweden, it looks like it could be cost-effective.

While the new implant offers substantial clinical benefits, including a lower risk of infections and other complications, it comes at a higher cost. A standard hip implant costs around 10,000 Swedish kronor, whereas the new model is approximately 18,000 kronor. Health economists are now evaluating whether the advantages justify the increased price. Hailer noted that the cost difference is even more pronounced in the UK. "For Sweden, it looks like it could be cost-effective," he stated, adding that researchers plan to follow up with surviving patients in eight to ten years.

The study, published in The Lancet, involved 24 hospitals in the UK and 20 in Sweden. Funding was provided by the Swedish Research Council and the UK's National Institute for Health and Care Research.

“

They who are still alive and have the energy to show up for a follow-up will of course be tried to be called.